Skip to main content

Table 2 Risk estimate in current concomitant use of CYP3A4 metabolized statins with clarithromycin within 30 days

From: A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death

Risk of death or hospitalisation

RR (95 % CI)

P value

Unadjusted risk

2.11 (1.79–2.48)

<0.001

Adjusted for

 Current agea

1.18 (1.00–1.40)

0.049

 Diabetes mellitus

1.60 (1.34–1.91)

<0.001

 Cardiovascular disease

1.33 (1.12–1.57)

0.001

 Other antibiotics

1.55 (1.28–1.87)

<0.001

Multivariable adjusted for

 age, diabetes mellitus, cardiovascular disease and other antibiotic therapy

1.02 (0.85–1.22)

0.85

  1. Estimates come from a generalised linear model using a log link function; confidence intervals are based on robust standard errors
  2. acurrent age as indicator variable of quintiles